AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06161103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prefabricated stainless steel crown group
Description: Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
Study NCT05502224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ergospirometry
Description: Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib PO will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study NCT06441097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
Study NCT05645367 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a post-hoc analysis of a cross-sectional study.
Study NCT05114447 — intervention group
Intervention type: OTHER
Intervention: Routine medical care
Description: Eligible subjects will be contacted from physicians, by telephone or directly when they attend the clinical centre for control visits. Once the patients have provided their signed informed consent, they will have to fill in the clinical form and to perform routine functional/clinical tests.~Subjects will be investigated at baseline (T0), at 6-month follow-up (T6) and at 12-month follow-up (T12).~All the possible variations that could occur in the patients' disease status and disease management, according to the routine medical care, will be registered and taken into account in the RISER study.~RISER study is not a clinical trial, but it is an observational study without any specific drug administration by the investigators. Participants will receive interventions, which can include medical products, such as drugs or devices, or procedures, as part of their routine medical care but they will not be assigned to specific interventions by the investigator as in a clinical trial.
Study NCT05114447 — intervention group
Intervention type: OTHER
Intervention: Telephone interview
Description: Eligible subjects will be contacted by telephone from trained personnel of the Research Unit. Once the signed informed consent is obtained by each enrolled subject, they will be invited to answer the phone questionnaire.~Subjects will be investigated at baseline (T0) and at 12-month follow-up (T12). Subjects fitting the epidemiological definition of severe/uncontrolled asthma will be invited at the Pisa clinical centre to have routine clinical/functional tests.~Each subject performing baseline clinical/functional tests at the Pisa clinical centre will be clinically and functionally re-assessed
Study NCT05658783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water foot bath
Description: Keeping keep in 42oC (42 Degrees Celsius) hot water for 20 minutes
Study NCT06206746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: May Health System
Description: The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
Study NCT05183620 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Feeling Hot sensor system
Description: The Feeling Hot sensor system consists of two temperature probes placed on the penis and the outer thigh of the test subject to measure skin temperature during erection
Study NCT06254781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Erythroid Maturation Agent
Study NCT04976257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogram
Description: Undergo angiogram
Study NCT04976257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheterization
Description: Undergo prostatic arterial catheterization
Study NCT04976257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga-labeled PSMA-11
Description: Given IV and IA
Study NCT04976257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT04892407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algeness® DF 3.5%
Description: dermal filler CE Mark approved for treatment of cheek and midface volume loss
Study NCT04892407 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm Voluma
Description: dermal filler CE Mark approved for treatment of cheek and midface volume loss
Study NCT04970082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FFR DWP
Description: FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
Study NCT05151341 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine collection (150ml)
Description: Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
Study NCT04970082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FFR
Description: FFR will be measured twice in the same lesion : One with the standard method and the other with the DWP method.
Study NCT06369688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEAL SKIIN CARES bundles
Description: The investigators developed a specialized PIP care bundle, named IDEAL SKIIN CARES, through extensive review of literature and expert insights, which will be utilized for training WSNs and patients in the intervention group. This comprehensive bundle comprises 15 key components aimed at effectively preventing PIs: (1) Incontinence care status; (2) Dehydration status; (3) Elevate at-risk surfaces; (4) Attention to attached devices to skin; (5) Lotion use; (6) Skin assessment; (7) Keeping repositioning; (8) Individualized up-to-date knowledge; (9) Individualized medical devices selection; (10) Nutrition status; (11) Caregiver (formal and informal) participation; (12) Activity assessment; (13) Reducing friction/shear forces; (14) Evaluate hemodynamic instability; (15) and Scrutinizing comorbidities.
Study NCT05151341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample (20 ml)
Description: Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research.
Study NCT05950503 — intervention group
Intervention type: RADIATION
Intervention: Hepatic MRI
Description: The patients will undergo hepatic MRI in pre-established timepoints
Study NCT06627725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-Family Communication
Description: Patient-Family Communication
Study NCT06369688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IDEAL SKIIN CARES bundles
Description: The investigators developed a specialized PIP care bundle, named IDEAL SKIIN CARES, through extensive review of literature and expert insights, which will be utilized for training WSNs and patients in the intervention group. This comprehensive bundle comprises 15 key components aimed at effectively preventing PIs: (1) Incontinence care status; (2) Dehydration status; (3) Elevate at-risk surfaces; (4) Attention to attached devices to skin; (5) Lotion use; (6) Skin assessment; (7) Keeping repositioning; (8) Individualized up-to-date knowledge; (9) Individualized medical devices selection; (10) Nutrition status; (11) Caregiver (formal and informal) participation; (12) Activity assessment; (13) Reducing friction/shear forces; (14) Evaluate hemodynamic instability; (15) and Scrutinizing comorbidities.
Study NCT06369688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEAL SKIIN CARES bundles workshop
Description: IDEAL SKIIN CARES bundles will be explained in detail by a trained research assistant in a workshop. This workshop is different from clinical training and following up about the IDEAL SKIIN CARES bundles.
Study NCT06369688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory care workshop
Description: An unrelated topic, specifically respiratory care will be held in a workshop. This training will involve the distribution of educational pamphlets, brochures, and visual posters outlining key aspects of respiratory care
Study NCT06017713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tDCS + symptoms provocation
Description: The treatment consists of 10 sessions of tDCS. Each tDCS session lasts 30 minutes at an intensity of 2mA and is preceded by a provocation of symptoms.
Study NCT05989165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil 5% Topical Solution
Description: Patient will be given minoxidil 5% topical solution, twice a day for 12 weeks
Study NCT05989165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microneedling
Description: Patient will be given microneedling treatment every 4 weeks
Study NCT05092425 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05922163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evidence-based VR simulation
Description: Evidence-based VR simulation videos on BTs for nursing students were developed, including 1) animated blood formation physiology and side effects of BT and 2) 360° BT nursing practice.
Study NCT06119529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3872386
Description: Administered either IV or SC.
Study NCT06119529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally.
Study NCT06119529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered either IV or SC.
Study NCT06444698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cookies that contain 50 grams of quinoa
Description: 250 grams of ground quinoa will be mixed with 250 grams of ready-to-use cookie flour and 100 gram of butter, one egg, and 75 gram of chocolate chips will be added. After mixing, the ingredients will be divided into (10) cookies (each cookie will continue 25 grams of quinoa) and bake them in oven for 9-11 mint at 190 °C. The placebo control group will receive cookies that continue the same ingredient but without quinoa and the cookies will look like the experimental group cookies. Cookies delivery will be every 3 to 4 days for each participants.
Study NCT06444698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cookies without quinoa
Description: The placebo control group will receive cookies that continue the same ingredient of experimental group but without quinoa and the cookies will look like the experimental group cookies.
Study NCT05548907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep restriction treatment
Description: Treatment consists of sleep restriction treatment for insomnia. In this treatment, participants limit their bedtimes to the time they actually sleep. If they sleep most of the time in bed again then bedtimes are slowly built up again. This treatment technique has already been studied in several trials and found to be effective.~Mode of delivery is an online booklet, online exercises and weekly telephone support
Study NCT05548907 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sleep diary monitoring
Description: As an active control condition people monitor their sleep with a sleep diary (also included in the sleep restriction intervention)
Study NCT04521803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose Rifampicin (RIF)
Description: Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
Study NCT05686525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Microwave Thermotherapy
Description: TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
Study NCT05686525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolisation
Description: In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
Study NCT04549272 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study NCT05992220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
Description: The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites.
Study NCT05992220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab plus bevacizumab
Description: Atezolizumab plus bevacizumab q3w
Study NCT05676437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stress radiography
Description: Radiographic examination during clinical stress test of knee laxity
Study NCT05546489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lymfit intervention
Description: Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
Study NCT06291363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol Hydrochloride
Description: Patients in the experimental group will receive esmolol during general anesthesia
Study NCT04796987 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Convolutional Neural Network
Description: Convolutional neural networks, a machine learning technique, have been used in several industrial and research fields increasingly. The development of computational units and the increasing amount of data led to the development of new methods on artificial neural networks. Deep learning (DL) is a multi-layered neural network in which feature extraction is done automatically. It extends traditional neural networks by adding more hidden layers to the network architecture between the input and output layers to model more complex and nonlinear relationships.
Study NCT05551247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg,sc,d3,Q3W;
Study NCT05551247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin (endostatin)
Description: 210mg,civ,d1-3,Q3W
Study NCT04738318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
Study NCT04738318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
Study NCT06551623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam Oral Solution 2 mg
Study NCT06551623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablets 0.5 g
Study NCT06551623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 Capsules 400 mg
Study NCT06456593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obefazimod
Description: Obefazimod is administered once-daily in fed condition (ideally at the same time in the morning).
Study NCT06456593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered QD in fed condition (ideally at the same time in the morning).
Study NCT06291363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in the standard of care group will receive saline as placebo during general anesthesia
Study NCT04852393 — intervention group
Intervention type: PROCEDURE
Intervention: Block
Description: cervical medial branch block
Study NCT01517321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0431/ONO-5435
Description: Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
Study NCT05893641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A regular training volume
Description: Participate will maintain their training volume of 35 h/week